International Journal of Oncology,
Journal Year:
2024,
Volume and Issue:
64(4)
Published: Feb. 13, 2024
Immune
checkpoint
molecules,
such
as
programmed
cell
death
1
(PD‑1)
and
ligand
(PD‑L1),
have
a
critical
role
in
regulating
immune
responses,
including
tumor
tissues.
Monoclonal
antibodies
against
these
known
inhibitors
(ICIs),
been
shown
to
be
effective
variety
of
cancers;
however,
significant
patient
populations
are
resistant
treatment.
Clinical
studies
date
that
ICIs
less
cancer
patients
with
bone
metastases.
The
effect
anti‑PD‑1/PD‑L1
on
metastases,
assessed
by
the
metastasis‑specific
response
classification
criteria,
was
relatively
low.
In
addition,
presence
metastases
showed
trend
toward
worse
progression‑free
survival
overall
treated
ICIs.
To
improve
efficacy
several
combination
therapies
under
investigation
certain
reported
better
responses.
present
review
summarizes
current
understanding
effects
based
clinical
preclinical
studies.
Cells,
Journal Year:
2025,
Volume and Issue:
14(5), P. 382 - 382
Published: March 5, 2025
The
peremptory
need
to
circumvent
challenges
associated
with
poorly
differentiated
epithelial
endometrial
cancers
(PDEECs),
also
known
as
Type
II
(ECs),
has
prompted
therapeutic
interrogation
of
the
prototypically
intractable
and
most
prevalent
gynecological
malignancy.
PDEECs
account
for
cancer-related
mortalities
due
their
aggressive
nature,
late-stage
detection,
poor
response
standard
therapies.
are
characterized
by
heterogeneous
histopathological
features
distinct
molecular
profiles,
they
pose
significant
clinical
propensity
rapid
progression.
Regardless
complexities
around
PDEECs,
still
being
administered
inefficiently
in
same
manner
clinically
indolent
readily
curable
type-I
ECs.
Currently,
there
no
targeted
therapies
treatment
PDEECs.
realization
new
options
transformed
our
understanding
enabling
more
precise
classification
based
on
genomic
profiling.
transition
from
a
provided
critical
insights
into
underlying
genetic
epigenetic
alterations
these
malignancies.
This
review
explores
landscape
focus
identifying
key
subtypes
mutations
that
variants.
Here,
we
discuss
how
correlates
outcomes
can
refine
diagnostic
accuracy,
predict
patient
prognosis,
inform
strategies.
Deciphering
underpinnings
led
advances
precision
oncology
protracted
remissions
patients
untamable
International Journal of Oncology,
Journal Year:
2024,
Volume and Issue:
64(4)
Published: Feb. 13, 2024
Immune
checkpoint
molecules,
such
as
programmed
cell
death
1
(PD‑1)
and
ligand
(PD‑L1),
have
a
critical
role
in
regulating
immune
responses,
including
tumor
tissues.
Monoclonal
antibodies
against
these
known
inhibitors
(ICIs),
been
shown
to
be
effective
variety
of
cancers;
however,
significant
patient
populations
are
resistant
treatment.
Clinical
studies
date
that
ICIs
less
cancer
patients
with
bone
metastases.
The
effect
anti‑PD‑1/PD‑L1
on
metastases,
assessed
by
the
metastasis‑specific
response
classification
criteria,
was
relatively
low.
In
addition,
presence
metastases
showed
trend
toward
worse
progression‑free
survival
overall
treated
ICIs.
To
improve
efficacy
several
combination
therapies
under
investigation
certain
reported
better
responses.
present
review
summarizes
current
understanding
effects
based
clinical
preclinical
studies.
